Wei Lin, M.D.
Wei Lin has served as a member of 2seventy bio’s board of directors since March 2023. He is currently the chief medical officer at Erasca, a precision oncology company focused on developing therapies for patients with RAS/MAPK pathway-driven cancers. Previously, he served as senior vice president and head of development at Nektar Therapeutics, an immunology company focused on developing immunotherapies for patients with cancer and autoimmune diseases. Before joining Nektar, he was the global development lead for cancer immunotherapy in lung cancer and head and neck cancer at Roche Genentech, and the Asia-Pacific site head for oncology product development at Roche. He brings a deep clinical development expertise from his experience in filing multiple INDs, to executing clinical trials across all phases, to global registration and launch. He led teams that supported the global approval of TECENTRIQ® (atezolizumab) in three indications, including the first advancement in first-line small cell lung cancer in three decades, the China approval of AVASTIN® (bevacizumab), ZELBORAF® (vemurafenib), and TARCEVA® (erlotinib), and FDA breakthrough therapy designation for bempegaldesleukin. Wei is a past recipient of the ASCO Young Investigator Award and the AACR-AstraZeneca Translational Lung Cancer Award. He was on faculty at MD Anderson Cancer Center, where he completed his medical oncology fellowship. Wei completed his internal medicine residency at Massachusetts General Hospital and received his M.D. from Harvard Medical School and his B.A. in physics from Haverford College.